Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02215


Open-label study with 30-day run-in phase and adaptive design component to include more subjects if deemed appropriate by investigators.

Study summary:

This is a within-subject, controlled open-label study seeking to determine if EPI-589 can alter the biochemical signature of PD as assessed by peripheral blood and brain imaging biomarkers. Data will also be collected on disease-relevant clinical measures will be collected.


Inclusion Criteria: - Hoehn and Yahr stage ≤ 3.0 - Ambulatory with or without assistance - Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., hormonal methods, including oral, subcutaneous, and intrauterine; barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 3 months after the last dose of study treatment. - Willingness and ability to comply with study procedures - If on medications for PD drugs, then medication regimen must be stable for 60 days prior to enrollment - Abstention from use of other investigative or nonapproved drugs for the duration of the trial. For Idiopathic Subjects - A diagnosis of idiopathic PD confirmed by the presence of bradykinesia plus one or both of the following symptoms: rigidity or resting tremor; and with an abnormal DaTscan consistent with a dopaminergic deficit - Age 40 to 75 years - Within 5 years of diagnosis of Parkinson's disease For Genetic Subtype Subjects - A confirmed diagnosis of PD plus a genetic diagnosis consistent with PD, specifically PINK1, parkin, LRRK2 or other mitochondrial genetic subtype - Age 21 to 75 years Exclusion Criteria: - Allergy to EPI-589 or other components of the EPI-589 tablet formulation - Use of antioxidant supplements, specifically vitamins E and C beyond the recommended daily allowance - Other Parkinsonian disorders - MoCA score of <24 - Revised Hamilton Rating Scale for Depression ≥ 11 - Parkinsonism due to drugs or toxins - Diagnosis of any other clinically significant neurologic disease that will confound the assessment of effect of study drug on disease progression - Malignancy within past two years - Pregnant or plans to become pregnant or breast feeding - History of stroke - History of brain surgery - Hepatic insufficiency with liver function tests (LFTs) >3 times upper limit of normal - Renal insufficiency as defined by creatinine > 1.5 times normal - End stage cardiac failure - Participation within past 3 months and for duration of study in a trial of a device, drug or other therapy for PD



Primary Contact:

Study Director
Matthew B Klein, MD FACS
Edison Pharmaceuticals

Backup Contact:


Location Contact:

Boston, Massachusetts 02215
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.